Mounjaro Dosage: The Titration Schedule, Explained

This page is reference, not instruction. It tells you what the FDA-approved prescribing information for Mounjaro publishes — a public document, checked against DailyMed on 13 July 2026 — so you can read your own prescription with understanding and ask better questions. It is not a plan for you. Your prescriber sets your dose, changes it, and decides when it should not change. Nothing here should be used to start, stop, adjust, split, stretch, skip or double a dose.

The direct answer

The FDA label for Mounjaro (tirzepatide) starts every patient at 2.5 mg injected under the skin once weekly. After four weeks, the dose goes to 5 mg once weekly. If more blood-sugar control is needed, the label allows increases in 2.5 mg increments after at least four weeks on the current dose, up to a maximum of 15 mg once weekly in adults. The label is explicit that 2.5 mg is a starting dose "not intended for glycemic control" — it exists to let your gut adapt. Mounjaro is also approved for children aged 10 and older with type 2 diabetes, where the label's maximum is 10 mg once weekly.

The label schedule, in a table

Two things people misread. First, four weeks is a minimum interval, not a schedule you are falling behind on. Plenty of people stay at 5 mg or 7.5 mg indefinitely because it is working; the label only permits an increase "if additional glycemic control is needed." A dose that is doing its job is not a dose you failed to escalate. Second, 15 mg is a ceiling, not a target. There is no clinical prize for reaching it, and gastrointestinal side effects are dose-related.

Missed doses are where people most often improvise, and it is the one place you should not. What the label publishes, as guidance to the prescriber, is that a missed dose may be taken as soon as possible within four days (96 hours) of the missed dose; if more than four days have passed, that dose is skipped and the next one is taken at the regular weekly time. That is what the document says — it is not a rule for you to apply on your own, and nothing in it authorises taking two doses close together. Do not double up. If you miss a dose, call your prescriber or pharmacist and follow what they tell you, not what a forum tells you.

Why titration is deliberately slow

Tirzepatide activates two gut-hormone receptors (GIP and GLP-1). Among other effects, it slows how fast the stomach empties. That is part of why it works — and it is exactly why a fast ramp makes people miserable. Nausea, vomiting, diarrhoea and constipation cluster in the days after a dose increase, and they are the most common reason people abandon the drug entirely. The four-week step is not caution theatre; it is the interval that lets the gut adapt before the next stimulus.

There is a second reason, specific to diabetes. Tirzepatide's effect on blood sugar is dose-dependent, and so is the risk to anyone whose other medications are already pushing glucose down. A slow ramp gives a prescriber time to see what is happening to your numbers and adjust the rest of your regimen before you land at a dose that is too much for the combination. More on that below.

The practical consequence: reaching a maintenance dose typically takes months, not weeks. If you are told you will be at a high dose by week six, something is wrong with the plan, not with you. Our GLP-1 dosing schedule explainer compares how the different drugs in this class ramp, and tirzepatide side effects covers what the ramp actually feels like.

Mounjaro and Zepbound are the same molecule

This is the fact that explains almost every confusing thing about access to this drug. Mounjaro and Zepbound are both tirzepatide, made by the same manufacturer, in the same 2.5 to 15 mg strengths, injected once weekly, with the same 2.5 mg start and the same four-week minimum steps. They are different approvals, not different chemistry.

So when a plan covers one and denies the other, it is not making a pharmacological judgement. It is applying a benefit rule: most plans cover drugs indicated for type 2 diabetes, and many exclude drugs indicated for weight loss outright. That is why two people on the identical molecule at the identical dose can pay wildly different amounts. Chemistry is not the variable. Coverage is.

What this does not mean: it does not mean the two products are interchangeable in your hands. The devices, cartons and dose counts are packaged differently, and the manufacturer's own labels state that a tirzepatide product should not be used together with another tirzepatide product or with a GLP-1 receptor agonist. Never substitute one brand's device for the other on your own, never combine them, and never let a dose be "made up" out of a different product or a different device. Switching brands is a prescription change made by a prescriber. Read tirzepatide: Mounjaro vs Zepbound and Mounjaro vs Ozempic if you are comparing options.

Blood sugar: the part dosage pages skip

Tirzepatide on its own rarely causes low blood sugar. Combined with insulin or a sulfonylurea (glipizide, glimepiride, glyburide), the risk goes up — because those drugs push insulin out regardless of what your glucose is doing, while tirzepatide is lowering it at the same time. The FDA label addresses this directly: when starting tirzepatide, prescribers are told to consider reducing the dose of concomitant insulin or insulin secretagogues to lower the risk of hypoglycemia.

Read that carefully. It is an instruction to the prescriber, not to you. Do not reduce your own insulin or sulfonylurea because you read that sentence, and do not stop anything on your own either. Bring it to your appointment and ask: "I'm on [insulin/sulfonylurea] — are you adjusting it as my tirzepatide dose goes up, and what should I do if my readings drop?" Ask how often to check, what number should prompt a phone call, and whether you should keep fast-acting glucose on hand. Metformin, by contrast, does not carry the same hypoglycemia risk on its own and is often continued alongside. If you take other prescriptions, run them through our interaction checker and bring the list to your visit.

What it costs — and what we cannot know

Prices and coverage rules move, so treat every number below as dated. Here is what was verifiable on 13 July 2026, from the manufacturer's own pages:

• Self-pay: Lilly's direct channel lists Mounjaro single-dose prefilled pens starting at $499 per month, the same headline price across all six strengths — the dose does not change the price. Taxes and fees are extra.
• Savings card, commercial insurance that covers Mounjaro: Lilly advertises as little as $25 for up to a 3-month prescription, with savings capped at up to $150 per one-month fill, an annual maximum of $1,950, and no more than 13 fills a year. The card as published expires 31 December 2026.
• Savings card, commercial insurance that does not cover Mounjaro: Lilly quotes as low as $499 for a one-month fill — the same ballpark as self-pay, not the $25 headline.
• Government insurance is excluded from manufacturer copay cards by law — Medicare, Medicare Part D, Medicare Advantage and Medicaid. This is the single most common reason a card that worked for a friend does not work for you.
• Medicare Part D plans may cover tirzepatide for type 2 diabetes; drugs approved only for weight loss have historically been excluded by statute — which is precisely why the Mounjaro/Zepbound distinction matters so much to older patients.

What we cannot tell you is what your plan will do, because your formulary, tier, prior-authorisation criteria and step-therapy rules are specific to your employer's contract. The honest answer is: your plan decides, and no article can know it. So call the number on the back of your card and ask these four questions, verbatim: (1) Is tirzepatide on my formulary, and under which brand? (2) What tier, and what is my cost at that tier? (3) Does it require prior authorisation or step therapy — and what exactly do I have to fail first? (4) Is there a quantity limit that would block a dose increase? Write down the answers and the call reference number. Our cost and coverage estimator can help you organise what you learn.

Two hard lines. Never misrepresent a diagnosis or a symptom to an insurer to obtain coverage — it is fraud, it can void your policy, and it is not a workaround anyone should offer you. And on compounded tirzepatide: compounded copies are not FDA-approved, and the agency does not review them for safety, effectiveness or quality. The FDA declared the tirzepatide shortage resolved in December 2024 and set deadlines in early 2025 after which compounding pharmacies could no longer make copies on shortage grounds. Whether any compounded product is appropriate or lawful in your situation is a conversation with a licensed clinician and pharmacist, not a decision to make from a website.

Disclosure: VidaBeacon may earn a commission from some links to care or product providers. It never changes what we write, no company has paid to appear on this page, and we name no telehealth provider or pharmacy here as a recommendation.

How to judge a prescriber or telehealth service

If you are getting tirzepatide through an online service, judge it on these, not on its ads. Does a licensed clinician in your state actually evaluate you, and can you reach the same one again? Do they take a full medication list — especially insulin and sulfonylureas — before prescribing? Do they follow the label's four-week minimum, or push a faster ramp? Do they dispense FDA-approved product from a licensed pharmacy, and will they name that pharmacy in writing? Is there a route to reach a human within 24 hours when you are vomiting and cannot keep water down? A service that will not answer those plainly has told you something.

Talk to your prescriber — and when to act now

Call the same day, or seek urgent care, for: severe or persistent abdominal pain, especially pain that bores through to your back (possible pancreatitis); vomiting you cannot stop, or signs of dehydration; symptoms of low blood sugar you cannot correct — shakiness, sweating, confusion; signs of an allergic reaction; or vision changes if you have diabetic retinopathy.

Book a conversation, don't improvise, if: a dose increase has left you unable to eat or work; you have missed doses and do not know what comes next; your blood sugar has been running low since starting; you are pregnant, planning pregnancy, or breastfeeding; you have a personal or family history of medullary thyroid carcinoma or MEN 2 (a boxed-warning contraindication on the label); you take a sulfonylurea or insulin; or your pharmacy has handed you a different brand or device than last month.

The one message worth carrying out of this page: the schedule above is what the label publishes, not a plan you execute. Do not self-adjust, do not double up, do not substitute one product for another. Bring the questions — that is the part that is yours to do. For the wider picture on this drug class, see GLP-1 medications explained and semaglutide, or browse weight and metabolism.